List of Olinvyk drug patents

Olinvyk is owned by Trevena.

Olinvyk contains Oliceridine.

Olinvyk has a total of 4 drug patents out of which 0 drug patents have expired.

Olinvyk was authorised for market use on 30 October, 2020.

Olinvyk is available in solution;intravenous dosage forms.

Olinvyk can be used as management of acute pain by intravenous injection.

Drug patent challenges can be filed against Olinvyk from October, 2024.

The generics of Olinvyk are possible to be released after 23 March, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8835488 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(9 years from now)

US9309234 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(9 years from now)

US11077098 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(9 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9642842 TREVENA Opioid receptor ligands and methods of using and making same
Mar, 2032

(9 years from now)

Exclusivity Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) Oct 30, 2025

Drugs and Companies using OLICERIDINE ingredient

NCE-1 date: October, 2024

Market Authorisation Date: 30 October, 2020

Treatment: Management of acute pain by intravenous injection

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic